Memorial Hospital Research Laboratories
The Daniel Higginson Lab
The Higginson lab focuses on alternative DNA double strand break repair pathways that become particularly important in tumors deficient in homologous recombination (e.g. BRCA1 or BRCA2 mutant tumors) and in tumors relatively deficient in non-homologous end-joining (e.g. HPV-associated tumors). These alternative pathways include alternative end-joining and single strand annealing. We employ advanced genome editing approaches to measure the full spectrum of repair events at a double strand break to quantify the use of both standard and alternative repair pathways. This approach allows for study of pathway tradeoffs that occur in the context of cancer-specific genetic alterations or when DNA damage response inhibitors (DDRi) are used. We seek to understand these pathways better in order to improve the therapeutic response to radiation and other DNA-damaging agents by finding rational combinations of DDRi to use in combination with radiation and matched to tumor-specific repair deficiencies.
Jonathan E Leeman, Yi Li, Andrew Bell, Suleman S Hussain, Rahul Majumdar, Xiaoqing Rong-Mullins, Pedro Blecua, Rama Damerla, Himanshi Narang, Pavithran T Ravindran, Nancy Y Lee, Nadeem Riaz, Simon N Powell, Daniel S Higginson. Human papillomavirus 16 promotes microhomology-mediated end-joining. Proc Natl Acad Sci USA. 2019 Oct 22; 116(43) 21573-21579.
Rama R. Damerla, Nancy Y. Lee, Daoqui You, Rekha Soni, Rachna Shah, Marsha Reynhold, Nora Katabi, Vanessa Wu, Sean M McBride, Chiaojung Jillian Tsai, Nadeem Riaz, Simon N Powell, N Esther Babady, Agnes Viale, Daniel S Higginson. Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy. JCO Precis Oncol. 2019;3:PO.18.00276.
Daniel S. Higginson, MD
- Physician-scientist Daniel Higginson studies a double-strand break repair pathway known as microhomology-mediated end joining, with the overall goal of improving the understanding of radiation treatment and providing insight into therapies for cancers deficient in homologous recombination.
- MD, Johns Hopkins University School of Medicine
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Daniel S. Higginson discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.